All
Fine-tuning, tailoring botulinum toxin injection techniques
February 1st 2007Berlin - Fine-tuning the botulinum toxin injection techniques and tailoring these techniques to each patient individually requires attention to certain details, and is the key to successful outcomes, according to one expert.
Be aware of lidocaine allergic contact dermatitis
February 1st 2007National report - As use of lidocaine for injectable local and topical anesthesia is increasing, dermatologists need to recognize that this amide anesthetic has the potential to cause allergic contact dermatitis, according to James Taylor, M.D., a dermatologist at The Cleveland Clinic Foundation, Cleveland.
Nexavar trial falls short of primary endpoint
January 9th 2007Emeryville, Calif. - Bayer Pharmaceuticals Corp., West Haven, Conn., and Onyx Pharmaceuticals, based here, have announced that a phase 3 trial administering Nexavar or placebo tablets combined with the chemotherapeutic agents carboplatin and paclitaxel in patients with advanced melanoma did not meet the trial's primary goal of improving progression-free survival (PFS)
Unexpected discovery has potential to effectively treat metastatic melanoma
January 9th 2007New York - Researchers working under grants from the National Institute of Allergy and Infectious Diseases (NIAID) to investigate a fungus that causes infection in people with AIDS, have in the process discovered a potential strategy for treating metastatic melanoma.
Artefill stakes claim as first approved permanent filler -'comfort level' remains to be seen
January 1st 2007National report - The Food and Drug Administration's (FDA) recent approval of the soft tissue filler Artefill (Artes Medical) marks a big milestone as the first permanent filler ever approved in the United States for wrinkle correction, and that distinction, alone, should give Artefill a unique marketing advantage.